2-([2-(4-CHLOROPHENOXY)ETHYL]THIO)-1H-BENZIMIDAZOLE
Modify Date: 2024-01-10 13:28:32
![2-([2-(4-CHLOROPHENOXY)ETHYL]THIO)-1H-BENZIMIDAZOLE Structure](https://image.chemsrc.com/caspic/408/312749-73-8.png)
2-([2-(4-CHLOROPHENOXY)ETHYL]THIO)-1H-BENZIMIDAZOLE structure
|
Common Name | 2-([2-(4-CHLOROPHENOXY)ETHYL]THIO)-1H-BENZIMIDAZOLE | ||
|---|---|---|---|---|
| CAS Number | 312749-73-8 | Molecular Weight | 304.794 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 509.6±56.0 °C at 760 mmHg | |
| Molecular Formula | C15H13ClN2OS | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 262.0±31.8 °C | |
Use of 2-([2-(4-CHLOROPHENOXY)ETHYL]THIO)-1H-BENZIMIDAZOLECLP-3094 is a potent BF3 (binding function 3)-directed inhibitor of the androgen receptor (AR). CLP-3094 inhibits AR transcriptional activity (IC50=4 μM)[1]. CLP-3094 is a selective, potent GPR142 antagonist[2]. |
| Name | 2-{[2-(4-Chlorophenoxy)ethyl]sulfanyl}-1H-benzimidazole |
|---|---|
| Synonym | More Synonyms |
| Description | CLP-3094 is a potent BF3 (binding function 3)-directed inhibitor of the androgen receptor (AR). CLP-3094 inhibits AR transcriptional activity (IC50=4 μM)[1]. CLP-3094 is a selective, potent GPR142 antagonist[2]. |
|---|---|
| Related Catalog | |
| In Vitro | CLP-3094 inhibits both an increase of intracellular Ca2+ concentration ([Ca2+]i) induced by L-tryptophan using CHO-K1 cells expressing GPR142 in the aequorin assay, and an accumulation of inositol phosphates using HEK293 cells expressing GPR142 in the SPA assay. The IC50 of CLP-3094 is 0.2 μM against 200 μM L-tryptophanfor the mouse receptor and 2.3 μM against 1 mM L-tryptophan for the human receptor in the aequorin assay. CLP-3094 also inhibits the insulin secretion from islets induced by both L-tryptophan and GPR142 agonists[2]. |
| In Vivo | CLP-3094 (30, 100 mg/kg; i.p. daily from Day 0 to Day 11) consistently displayed sig-nificantly lower severity of arthritis scores than vehicletreated mice[2]. Animal Model: CAIA mouse model (Female DBA1/J mice were i.v. administered with2 mg of anti-collagen antibody, followed by i.p. administration of 50 μg of LPS)[2] Dosage: 30, 100 mg/kg Administration: I.p. daily from Day 0 to Day 11 Result: Dose-dependently reduced, by not much, the arth-ritis scores. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 509.6±56.0 °C at 760 mmHg |
| Molecular Formula | C15H13ClN2OS |
| Molecular Weight | 304.794 |
| Flash Point | 262.0±31.8 °C |
| Exact Mass | 304.043701 |
| LogP | 5.08 |
| Vapour Pressure | 0.0±1.3 mmHg at 25°C |
| Index of Refraction | 1.693 |
| 2-(1H-benzimidazol-2-ylsulfanyl)ethyl 4-chlorophenyl ether |
| MFCD00805733 |
| 1H-Benzimidazole, 2-[[2-(4-chlorophenoxy)ethyl]thio]- |
| 2-{[2-(4-Chlorophenoxy)ethyl]sulfanyl}-1H-benzimidazole |